This presentation will review data from HER2 Climb, a global, randomized, double-blind, controlled trial evaluating Tukysa (tucatinib) versus placebo, each in combination with trastuzumab and capecitabine. It will also review key highlights such as study design, patient characteristics as well as go over safety and efficacy data.